<DOC>
	<DOCNO>NCT02575807</DOCNO>
	<brief_summary>This 2-part , phase 1/2 trial examines side effect cancer immunotherapy CRS-207 alone combination epacadostat ( INCB024360 ) , indoleamine 2,3-dioxygenase ( IDO1 ) inhibitor , see well work treat patient ovarian , fallopian tube , peritoneal cancer progress platinum-based chemotherapy within 6 month . CRS-207 weaken ( attenuate ) form Listeria monocytogenes genetically modify reduce ability cause disease , maintain ability stimulate potent immune response kill tumor cell . Epacadostat potent , highly selective IDO1 inhibitor stimulate immune cell activation tumor .</brief_summary>
	<brief_title>Safety Efficacy CRS-207 With Epacadostat Platinum Resistant Ovarian , Fallopian , Peritoneal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<criteria>Subjects histologicallyconfirmed platinumresistant epithelial ovarian , fallopian , primary peritoneal cancer disease progression within 6 month complete platinum base chemotherapy Has measurable/assessable disease define RECIST v1.1 Part 1 : tumor must accessible safe biopsy baseline Part 2 : subject must agree pair tumor biopsy lesion baseline treatment lesion biopsied acceptable clinical risk ( judged investigator ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Exclusion Criteria Has platinumrefractory disease ( progression prior platinumbased chemotherapy ) ; Had major surgical procedure within 4 week prior dose Has clinically significant ascites Prior chemotherapy regimens Part 1 : previous treatment &gt; 4 chemotherapy regimen locally advance metastatic disease Part 2 : previous treatment &gt; 2 chemotherapy regimen locally advance metastatic disease Prior monoclonal antibody within 4 week study Day 1 Has history listeriosis previous treatment listeriabased immunotherapy Has know allergy penicillin sulfa antibiotic Has immunodeficiency disease immunecompromised state Has history autoimmune disease receive prior immune checkpoint inhibitor ( e.g. , antiCTLA4 , antiPD1 , anti PDL1 ) antibody drug specifically target Tcell costimulation IDO inhibitor History organ transplant require use immunosuppressive therapy Has prosthetic heart valve ; major implant ( ) device ( ) place within 12 month screen ; current prior history infection clinically significant adverse event associate implant ( ) device ( ) easily remove Currently receive therapy UDPglucuronosyltransferase 1A9 inhibitor include diclofenac , imipramine , ketoconazole , mefenamic acid , probenecid Receiving monoamine oxidase inhibitor ( MAOIs ) drug significant MAOI activity ( meperidine , linezolid , methylene blue ) within 21 day screen Had prior serotonin syndrome Has clinically significant heart disease History presence abnormal ECG consider clinically meaningful Is pregnant breastfeeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Ovarian cancer</keyword>
	<keyword>Fallopian cancer</keyword>
	<keyword>Primary peritoneal cancer</keyword>
</DOC>